SCHEMBL2993013

SCHEMBL2993013

Cc1cc(Cl)ccc1NC(=O)C(Cc1nc2ccc(C(=O)c3ccccc3)cc2[nH]c1=O)=NNC(=O)c1ccncc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.85
GRB7 Q14451 3/20 0.42
ALDH1A1 P00352 4/20 0.39
RAB9A P51151 3/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 2/20 0.39
KDM4E B2RXH2 5/20 0.39
MAPT P10636 5/20 0.39
NPC1 O15118 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 3/20 0.38
HTT P42858 3/20 0.38
ABL1 P00519 3/20 0.38
CYP1A2 P05177 2/20 0.38
ABCC4 O15439 1/20 0.38
USP2 O75604 1/20 0.38
CYP2C9 P11712 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2993011 1.00 PTGES (0.85) PTGESGRB7ALDH1A1RAB9AHPGD
SCHEMBL2988056 0.77 PTGES (0.60) PTGESALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL2988054 0.77 PTGES (0.60) PTGESALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL12336929 0.67 POLB (0.64) PTGESALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL16927680 0.64 ALDH1A1 (0.72) GRB7ALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL11819922 0.62 MAPT (0.68) RAB9AHPGDSMN1; SMN2POLBKDM4E
SCHEMBL12909208 0.60 ALDH1A1 (1.00) ALDH1A1RAB9AHPGDSMN1; SMN2POLB
SCHEMBL30694320 0.60 MAPT (0.74) ALDH1A1SMN1; SMN2MAPTLMNACYP1A2
SCHEMBL29129826 0.60 MAPT (0.74) ALDH1A1SMN1; SMN2MAPTLMNACYP1A2
SCHEMBL4065084 0.60 ABL1 (0.64) ALDH1A1RAB9AHPGDSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) 2010-07-22 US disclosed
EP-2068873-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS Pharma 2100 (DK) 2009-06-17 EP disclosed
WO-2008031440-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS PHARMA 2100 (DK) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS ODC1, OTC, ACACB PTGES 1829/4885GRB7 3815/4885ALDH1A1 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.